CTOR (Citius Oncology) Net Income (Continuing Operations) : $-12.70 Mil (TTM As of Sep. 2023)

View and export this data going back to 2024. Start your Free Trial

What is Citius Oncology Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Citius Oncology's Net Income (Continuing Operations) for the six months ended in Sep. 2023 was $-12.70 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Sep. 2023 was $-12.70 Mil.

Citius Oncology Net Income (Continuing Operations) Historical Data

The historical data trend for Citius Oncology's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Citius Oncology Net Income (Continuing Operations) Chart

Citius Oncology Annual Data

Trend

Sep22

Net Income (Continuing Operations)

-5.43

Citius Oncology Semi-Annual Data
	Sep22	Sep23
Net Income (Continuing Operations)	-5.43	-12.70

Citius Oncology Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Sep. 2023 was $-12.70 Mil.

Citius Oncology (NAS:CTOR) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Citius Oncology Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Citius Oncology's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

Citius Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Citius Oncology Inc (NAS:CTOR) » Definitions » Net Income (Continuing Operations)

Comparable Companies

Traded in Other Exchanges

N/A

Address

420 Lexington Ave, Suite 2446, New York, NY, USA, 10170

Website

Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.